Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
AVDL - Avadel Pharmaceuticals plc
Market Cap 1.07B P/E - EPS this Y 77.00% Ern Qtrly Grth -
Income -106.22M Forward P/E -73.21 EPS next Y 247.80% 50D Avg Chg -4.00%
Sales 95.15M PEG -1.90 EPS past 5Y - 200D Avg Chg 37.00%
Dividend N/A Price/Book N/A EPS next 5Y 15.00% 52W High Chg -17.00%
Recommedations 1.60 Quick Ratio 2.37 Shares Outstanding 96.27M 52W Low Chg 202.00%
Insider Own 4.77% ROA -34.45% Shares Float 83.23M Beta -
Inst Own 78.83% ROE -99.52% Shares Shorted/Prior 11.66M/11.77M Price 13.91
Gross Margin 94.62% Profit Margin -111.64% Avg. Volume 867,117 Target Price 24.60
Oper. Margin -30.70% Earnings Date Nov 6 Volume 699,396 Change -1.07%
Healthcare | Drug Manufacturers - Specialty & Generic | Ireland
About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals plc News
12/12/24 Independent Non-Executive Chairman of the Board of Avadel Pharmaceuticals Picks Up 16% More Stock
12/11/24 Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy
11/14/24 Avadel Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
11/13/24 Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
11/13/24 Avadel Pharmaceuticals PLC (AVDL) Q3 2024 Earnings Call Highlights: Strong Patient Growth and ...
11/12/24 Avadel: Q3 Earnings Snapshot
11/12/24 Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results
11/04/24 Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12
11/01/24 US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle
11/01/24 Loss-Making Avadel Pharmaceuticals plc (NASDAQ:AVDL) Expected To Breakeven In The Medium-Term
10/31/24 Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation
10/24/24 Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep Advances
10/18/24 Avadel wins FDA approval for narcolepsy drug Lumryz in children
10/18/24 Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz
10/17/24 Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
10/09/24 Avadel Pharmaceuticals PLC (AVDL) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
09/25/24 Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent
09/03/24 Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)
08/28/24 Avadel Pharma Shares Fall After Split Decision in Legal Fight Over Narcolepsy Drug
08/28/24 Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
MCHUGH THOMAS S Chief Financial Offi.. Chief Financial Officer Aug 14 Buy 14.45 2,000 28,900 78,500 08/14/23
Divis Gregory J Chief Executive Offi.. Chief Executive Officer Aug 10 Buy 13.1997 10,000 131,997 159,100 08/10/23
Palczuk Linda Director Director May 09 Buy 14.76 2,500 36,900 52,400 05/10/23
Glass Geoffrey Michael Director Director May 31 Buy 2.14 45,000 96,300 45,000 06/03/22
Ende Eric J Director Director May 31 Buy 2.22 35,000 77,700 134,900 06/01/22
Palczuk Linda Director Director May 27 Buy 1.60 10,000 16,000 47,900 05/31/22
MCHUGH THOMAS S Chief Financial Offi.. Chief Financial Officer May 27 Buy 2.1379 50,000 106,895 71,500 05/31/22
Ende Eric J Director Director May 27 Buy 2.4498 15,000 36,747 99,900 05/31/22
Divis Gregory J Chief Executive Offi.. Chief Executive Officer May 27 Buy 2.05 50,000 102,500 149,100 05/31/22
Thornton Peter J. Director Director May 27 Buy 1.69 50,000 84,500 83,055 05/31/22
McCamish Mark Anthony Director Director Sep 18 Buy 5.78 171,000 988,380 171,000 09/18/20